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Peptoids, a class of peptidomimetic, have gained considerable attention as potential therapeutic 
agents due to properties such as biocompatibility and resistance to enzymatic degradation. In 
linear peptoids, conformational heterogeneity can arise due to cis/trans isomerization around the 
backbone tertiary amide bond which has led to an increasing interest in cyclic peptoids. Biaryl 
linkages appear as a common structural motif in many synthetic and naturally occurring cyclic 
peptides but they are yet to be utilized in the formation of cyclic peptoids. Herein, we describe 
the application of a solid-phase Suzuki cross-coupling strategy as a means to prepare of a series 
of biaryl-linked cyclic peptoids. The methodology presented allows access to a range of novel 
biaryl containing cyclic peptoids with varying ring sizes.  
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Introduction 
 Peptoids (N-substituted glycines) belong to a class of synthetic 
molecules known as peptidomimetics, so named because of their 
similarity in structure to peptides (Fig. 1).
1,2
 Like peptides, 
peptoids are oligomeric in nature and they contain side-chains 
(R) which may comprise of a wide variety of functional groups. 
However, a peptoid’s backbone is devolved entirely of tertiary 
amide bonds, and, this in turn gives them a range of different 
physical and biological properties to peptides. 
For example, peptoids are highly resistant to enzymatic 
degradation,
3
 making then desirable molecules for a range of 
biological applications including imaging probes,
4
 
antimicrobials,
5-7
 antifungal
8
 and anticancer
4
 agents. In addition 
the lack of an amide NH within the backbone means that there is 
no capacity to use hydrogen bonding to stabilize the formation of 
discreetly folded secondary structures. Peptoids thus display an 
increased conformational flexibility over peptides, and 
controlling the cis-trans isomer profile in the backbone can be 
challenging.
9
 
This lack of a defined (or inherent) secondary structure in 
many peptoids presents an obstacle to their use as therapeutics 
due to the fact that good selectivity and binding affinity for a 
particular target often requires conformational rigidity.
10,11
 
Cyclisation offers a well-established process to modulate 
conformational flexibility in peptides
12, 13
 and leading on from 
this various strategies have been developed to cyclise peptoids. 
These include solution phase head-to-tail condensation,
14-17
 side-
chain “stapling” via Grubbs metathesis,
18
 halide substitution
19
 
and copper-catalysed azide-alkyne cycloaddition (CuAAC).
20, 21
  
Within our laboratory we are interested in the development of 
new building blocks and approaches that can be used to access 
biaryl containing cyclic peptides.
22 
The biaryl motif is commonly 
found in a range of important naturally occurring peptides 
including Vancomycin and the Biphenomycins as well as 
synthetic Arylomycin A2.
23, 24 
The biaryl motif has also received 
considerable attention from the pharmaceutical industry and it 
appears commonly in many compounds that have activity as anti-
fungal, anti-tumour, anti-hypertensive and anti-inflammatory 
agents.
25-27
 Given the attention directed towards biaryl motifs in 
peptide chemistry
28-30
 it is surprising that within the field of 
peptoid chemistry little work in this area has been reported.
31
 
Elegant recent work by Nam and Seo demonstrated the 
application of a Suzuki-Miyaura cross-coupling strategy as a 
means to access linear peptoids containing novel biaryl 
monomers.
32
 The aforementioned work utilized an intermolecular 
Suzuki cross-coupling process (i.e. arylboronic acid added to an 
aryl-halide monomer on resin) and to the best of our knowledge 
the corresponding intramolecular reaction has not yet been 
exploited to access biaryl containing cyclic peptoids.  
Herein, we report the preparation of a series of novel cyclic 
peptoids scaffolds that contain a biaryl linkage. Preparation of a 
range of ring sizes are demostrated and ring clourse has been 
achieved using on resin Suzuki cross-coupling strategy.  
 
Results and Discussion 
In order to access cyclic peptoids via a Suzuki cross-coupling 
approach the linear parent peptoid has to contain both an 
aromatic halide (e.g. bromide or iodide) and an aromatic boronic 
acid. The established sub-monomer peptoid synthesis strategy
1
 
was used to build up the linear peptoid on Rink Amide resin and 
incorporation of the required aromatic halide was achieved using 
commercially available, 3-iodobenzylamine (1) (Scheme 1).  
Incorporation of the aromatic boronic acid component was 
achieved using commercially available 3-carboxyphenyl boronic 
acid MIDA ester (2) with diisopropylcarbodiimide (DIC, Scheme 
1). The boronic acid (2) is protected with N-methyliminodiacetic 
acid (MIDA), deprotection of which is afforded by treatment in 
aqueous base at room temperature.
33
 MIDA boronates have been 
shown to be highly air stable, resistant to a wide variety of 
synthetic conditions
34
 and previous work within the group in 
which MIDA boronate-containing peptides were synthesised, 
confirms their stability towards amide bond coupling 
conditions.
22
  
The sequence of the first linear peptoid (3) chosen for 
cyclisation was designed to allow a relatively unstrained ring 
system to be accessed. We also incorporated Boc-protected 
amino butane monomers (Boc-NLys) to aid solubility upon 
peptoid cleavage from the resin. We wanted to carry out the 
cyclisation/ Suzuki cross-coupling whilst the parent linear 
peptoid (3) was still on resin. The advantages of carrying out the 
cross-coupling reaction whilst on resin are two-fold: firstly, there 
is no need to cleave and purify the linear parent peptoid which is 
not only time consuming, but can often result in loss of overall 
yield. Secondly, after the Suzuki cross-coupling reaction has 
been carried out, any unreacted reagents (e.g. metals) and side-
products can simply be removed by washing the resin, making 
purification of the final cyclic product easier. For the Suzuki 
cross-coupling we selected reaction conditions based on the 
previously reported work of Nam and Seo
32
 and our own 
experiences of working with MIDA-protected amino acids.
22
  
Vancomycin Arylomycin A2 
Biphenomycin B 
α-peptide α-peptoid 
Figure 1. Comparison of α-peptide and α-peptoid structures. 
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The cyclisation of the on resin linear peptoid (3) was therefore 
attempted using tetrakis palladium (5 mol%), Buchwald’s ligand, 
and K2CO3 in DMF at 80 °C for 8 h. It should be noted that as the 
reaction procedure used K2CO3 in excess we did not carry out a 
separate deprotection step for the MIDA-protected boronate ester 
prior to carrying out the on resin Suzuki cross-coupling reaction. 
Following cleavage from the resin (TFA/DCM) cyclic peptoid 5 
was isolated in a 15% yield as a water soluble white solid after 
reverse phase semi-preparative HPLC purification. While not 
isolated it is worth noting that the un-cyclised peptoid by-product 
(6) was observed in the LCMS of the crude reaction mixture.  
 
4 
5 
3 
6 
Scheme 2. Solid phase cyclisation of parent linear peptoid (3) into resin bound cyclic peptoid (4) via Suzuki cross-coupling, followed by 
cleavage from the resin to give the free cyclic peptoid (5). 
7 
9 
10 
Scheme 3. Solid phase cyclisation of parent linear peptoid (7) into resin bound cyclic peptoid (8) via Suzuki cross-coupling, followed by 
cleavage from the resin to give the free cyclic peptoid (9). 
3 
2 
Scheme 1. Incorporation of 3-iodobenzylamine (1) and 3-carboxyphenylboronic acid MIDA ester (2) into a linear peptoid (3). 
1 2 
3 
8 
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Linear peptoid Cyclic peptoid
a
 Yield
b
 (%) 
                     3                     5 
15 
                     7                     9 
9 
                  11                   17 
23 
                    12                   18 
22 
                   13                              19 
14 
                   14                         20 
13 
                   15 
                        21 
3 
                    16 
                        22 
17 
Table 1. Library of linear and cyclic peptoids 
 
a
Cyclic peptoids synthesized from linear parent peptoids under the conditions shown in Schemes 3 and 4 
b 
Isolated yields are calculated assuming that parent linear peptoids were synthesized with full conversion  
  
 5 
Next, we wanted to probe the effects of flexibility and overall 
sequence length of the linear peptoid chain on the cyclisation 
reaction. To test this, we replaced one of the NLys residues with 
a glycine monomer (increase in flexibility) and the synthesis of 
the linear parent peptoid (7) was completed by addition of 3-
carboxyphenylboronic acid to the N-terminus as shown in 
Scheme 3. Suzuki cross-coupling, cleavage from the resin and 
subsequent HPLC purification gave the biaryl-containing cyclic 
peptoid 9 in 9% yield (Scheme 3). It should be noted that ESI 
LCMS analysis of the crude reaction mixture prior to HPLC 
purification again showed that the corresponding dehalogenation/ 
deboronated product (10) was present.  
Having successfully isolated biaryl-containing cyclic peptoids 
5 and 9, we then proceeded to synthesise a small library of linear 
peptoids containing both an aromatic iodide and regio-isomeric 
MIDA-protected boronates (Table 1, 11-16). We carried out the 
Suzuki cross-couplings on each linear peptoid using the same 
reaction conditions in order to enable a simple comparison 
regarding the ease of ring formation (Table 1). Biaryl-containing 
cyclic peptoids were isolated from all of the linear sequences 
investigated, however, the isolated yields varied. Perhaps 
predictably, the longer sequences (13-16) appeared to be more 
difficult to cyclise, presumably due to a larger entropic penalty 
associated with constraining more flexible chains. With the 
exception of cyclic peptoids 9 and 20, in each case, the yield of 
the cyclic peptoid recovered was lower as the sequence increased 
in length. For the shorter linear peptoids containing the 3-MIDA 
boronate building block (i.e. compare 3 and 7) incorporation of a 
less hindered glycine monomer into the sequence (7) reduced the 
yield of the cyclic peptoid obtained (i.e. compare 5 and 9). This 
may indicate that the NLys monomer confers some level of 
secondary structure in the linear peptoid (3) that makes the cross-
coupling cyclisation reaction more favorable, whereas the extra 
flexibility conferred by the glycine monomer in 7 results in a 
greater entropic penalty having to be paid. Interestingly, the 
opposite is seen for the longer peptoids (i.e. 21 and 22) with the 
glycine-containing linear peptoid (16) cyclising more readily than 
the NLys-containing counterpart (15).  
For the shorter linear peptoids containing the 4-MIDA 
boronate building block (11 and 12), the presence of the NLys 
side-chain versus the glycine monomer appeared to make little 
difference to the efficiency of cyclisation, however, both 
resulting cyclic peptoids (17 and 18) were isolated in higher 
yields than the cyclic peptoids (5 and 9) formed from the 
corresponding shorter 3-MIDA boronate containing linear 
peptoids (3 and 7). This perhaps suggests that the formation of 
3,4-biaryl-linked cyclic peptoids (17 and 18) is favored over the 
formation of the corresponding 3,3-biaryl-linked cyclic peptoids 
(5 and 9). The same trend is also seen as peptoid sequence length 
is increased, i.e. 3,4-biaryl-linked cyclic peptoid 22 was isolated 
in a higher yield than the corresponding 3,3-biaryl-linked cyclic 
peptoid 20. However, given that the isolated yields in all of the 
aforementioned cases were not significantly different, it is 
difficult to draw any definitive conclusions from the data 
obtained. To gain more accurate information would require the 
linear peptoids to be cleaved and purified prior to Suzuki cross-
coupling, but as discussed earlier the on-resin cyclisation confers 
many advantages in the overall synthetic strategy.  
Conclusions 
The primary aim of this study was to prepare a series of linear 
peptoids with suitable functionality that could be cyclised via an 
on-resin Suzuki cross-coupling in order to obtain novel biaryl-
linked cyclic peptoids. This was achieved and a small library of 
cyclic peptoids with varying ring sizes and differing biaryl 
connectivity (i.e. 3,3- and 3,4-biaryl linkages) were prepared and 
isolated. With the initial concept established, optimization of the 
on-resin cyclisation reaction is now ongoing and the formation of 
bi-cyclic biaryl-containing peptoids via application of novel 
MIDA-protected monomers is being explored. The biaryl-linked 
cyclic peptoids prepared are also undergoing biological 
evaluation and the results will be reported in due course.  
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Research Highlights 
 Synthesis of MIDA boronate-containing 
linear peptoids 
 On resin Suzuki cross-coupling of linear 
peptoids 
 Preparation of novel biaryl-linked cyclic 
peptoids 
 
 
